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LEADING ARTICLECranial Nerve Palsy Should Not Be Included within a Primary Composite
Endpoint in Carotid Surgery Trials
G.J. de Borst a,*Carotid endarterectomy (CEA) is the most commonly per-
formed surgical procedure for the treatment of extracranial
cerebrovascular atherosclerosis and the risk of major peri-
operative neurologic complications has been thoroughly
documented. By contrast, the incidence and signiﬁcance of
iatrogenic injury to cranial nerves during the procedure has
not been so rigorously scrutinized. Cranial nerve palsy (CNP)
is a recognized complication of CEA and its reported fre-
quency (3e23%) varies according to study design, method
of diagnosing the injury and whether or not the patient was
assessed independently by a Neurologist.
The largest available series where patients were studied
before and after surgery was the European Carotid Surgery
Trial (ECST). They observed 88 motor cranial nerve injuries
among 1739 patients giving an early CNP rate of 5.1% (95%
CI 4.1e6.2), falling to 0.5% (95% CI 0.24e0.98) at 4 months,
none of which subsequently resolved.1 Asymptomatic CNP
was not documented by the ECST and this probably
contributed to the relatively low risk of CNP compared with
other prospective studies which utilized more sophisticated
testing modalities (e.g. otolaryngoscopy). The 5.1% risk of
postoperative CNP in ECST is also lower than the 8.6% risk
reported in the North American Symptomatic Carotid End-
arterectomy (NASCET) trial.2 In ECST, the initial clinical
assessment was made by the operating surgeon and the
patient was not examined by a neurologist until a few
months following surgery. For these reasons it is likely that
the ECST data under-estimate the immediate postoperative
risk. Nevertheless, ECST does provide reliable data on the
prevalence of persisting symptomatic deﬁcits during longer-
term follow-up, observing that the rate of permanent CNP
was very low (0.5%).
To minimize the risks of CNP, carotid angioplasty with
stenting (CAS) was developed as an alternative to CEA. In
the International Carotid Stenting Study (ICSS),3 45 CNPs
(5.5%) were observed in 821 patients allocated to surgery,
of which only one (0.1%) was judged to be disabling at one
month.3,4 Only two CEA patients suffered CNPs which did
not resolve in the long-term and the median duration ofa Department of Vascular Surgery, University Medical Center Utrecht, The
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days). In the Stent-Protected Angioplasty Versus Carotid
Endarterectomy (SPACE-1) trial, a transient CNP in the early
postoperative period was documented in 17 (8.2%) patients
after eversion CEA and in 25 (8.1%) patients after conven-
tional CEA.5 When all the European randomized CAS vs CEA
trial data were combined, the mean CNP rate after CEA was
6.0%, suggesting that while the rates of peri-operative
stroke or death after CEA may have reduced over the last
two decades, the same cannot be said of CNP.6
In the North-American Carotid Revascularization Endar-
terectomy versus stenting Trial (CREST), neurologic evalua-
tions were conducted prior to treatment and then at 24e48
hours post-intervention, one month, three months and then
annually.7 CNP was observed in 0.3% of CAS patients and
4.7% of CEA patients, although another paper from CREST
reported a 5.0% CNP rate after CEA.8 In the early post
intervention period, CAS patients reported less difﬁculty in
eating and swallowing compared with CEA patients. How-
ever, by 12 months CNP was not associated with a sustained
impact on HRQOL (Health related quality of life).7
Recently, Fokkema et al. presented CNP data from the
Vascular Study Group of New England (VSGNE) in 6,878
patients undergoing CEA between 2003 and 2011.9 The
surgeon-observed CNP rate was determined at the time of
discharge and again at a median of 12 months. The preva-
lence of early CNP was 5.6% (382 patients) and most were
transient. Only 47 patients (0.7%) had a persisting CNP at 12
months. These data are, therefore, very similar to what was
observed in the randomized trials with independent
Neurologist scrutiny.
VSGNE also observed that a prior history of ipsilateral
CEA or cervical irradiation (often considered to confer an
increased risk of CNP) were not actually associated with a
signiﬁcant increase in CNP.9 These observations are
consistent with a recent meta-analysis of CNP in CEA pa-
tients with a prior history of cervical irradiation (12 studies,
157 patients) which observed a prevalence of 9.2% (95% CI
3.7%e21.1%).10 In this meta-analysis, most of the CNPs
were transient and had completely resolved within several
weeks. Six studies reporting on this speciﬁc endpoint did
not report any CNP problems at all. These data suggest that
a history of prior cervical irradiation should not be consid-
ered to be an absolute contra-indication to performing CEA.
Although most surgeons consider CNPs to be relatively
minor (compared with central neurological morbidity),
multiple or bilateral CNPs can be quite disabling, particularly
if the swallowing mechanism or laryngeal airway are
affected. The overall prevalence of CNP is similar to the
584 G.J. de Borstcomposite endpoint of death, stroke and myocardial infarc-
tion after CEA and some believe that CNP should be included
within any composite outcome analysis. However, the 5%
prevalence of CNP (mostly transient) should not deﬂect
attention away from the most critical priority of preventing
stroke and stroke related death. To date, there is no evidence
that by excluding CNP from the composite primary endpoint
in the randomized trials of CAS vs CEA, that any of the con-
clusions would have been altered. Randomized controlled
trials (RCT) are designed to see if the intervention does or
does not provide a better outcome than the gold standard
treatment of the time. In some of the more recent ran-
domized trials comparing CAS with CEA, the primary
endpoint has included death, stroke, and myocardial infarc-
tion within 30 days. Many consider that the inclusion of
myocardial infarction within the primary endpoint was
probably an error11 and this would be further compounded
by the inclusion of CNP, because this would imply that a
subclinical CNP was equally as important as death. In short,
the efﬁcacy of CEA should not be confused with safety. CEA is
performed to reduce the incidence of death & stroke and it
does this, but at a short term cost of procedural complica-
tions that should be counted on the safety side. CNP is a
recognized complication of CEA just like a femoral haema-
toma is a complication of CAS. Both should be recorded, but
neither should be considered primary endpoints.
In conclusion; the risk of CNP after CEA persisting beyond
hospital discharge is approximately 6%. The vast majority
will resolve over the ﬁrst few months and permanent def-
icits are rare (<1%). A very small proportion of CNPs will,
however, be disabling and patients should be given clear
and accurate information regarding the likelihood of sus-
taining such an injury before undergoing surgery. Finally;
the very low risk of suffering a permanent or disabling CNP
should not detract from the signiﬁcant beneﬁt conferred by
CEA (regarding stroke prevention), especially in the early
time period after onset of symptoms.
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